Arcellx (ACLX) Declined Despite Positive Clinical Trial Results

1 month ago 19

Soumya Eswaran

Fri, February 6, 2026 astatine 7:35 AM CST 3 min read

Baron Funds, an concern absorption company, released its fourth-quarter capitalist missive for the “Baron Health Care Fund”. A transcript of the missive tin beryllium downloaded here. The money roseate 13.10% (Institutional Shares) successful the quarter, compared to a 11.92% summation for the Russell 3000 Health Care Index (benchmark) and a 2.40% summation for the Russell 3000 Index (the Index). The Fund returned 10.28% for the afloat year, compared to 14.56% and 17.15% gains for the indexes, respectively. Strong banal enactment successful biotechnology contributed to the Fund’s comparative gains successful the quarter. The Fund seeks to put successful businesses with secular maturation opportunities, a sustainable competitory edge, and beardown management. The steadfast believes that healthcare is simply a beardown assemblage successful the U.S. economy, offering charismatic concern opportunities with affirmative momentum heading into 2026. Please reappraisal the Fund’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, Baron Health Care Fund highlighted Arcellx, Inc. (NASDAQ:ACLX) arsenic a show detractor. Headquartered successful Redwood City, California, Arcellx, Inc. (NASDAQ:ACLX) develops assorted immunotherapies for patients with crab and different incurable diseases. The one-month instrumentality of Arcellx, Inc. (NASDAQ:ACLX) was 1.01%, and its shares gained 0.04% of their worth implicit the past 52 weeks. On February 5, 2026, Arcellx, Inc. (NASDAQ:ACLX) banal closed astatine $66.94 per stock with a marketplace capitalization of $3.87 billion.

Baron Health Care Fundstated the pursuing regarding Arcellx, Inc. (NASDAQ:ACLX) successful its 4th fourth 2025 capitalist letter:

"Arcellx, Inc. (NASDAQ:ACLX) is processing compartment therapies for aggregate myeloma, including pb campaigner anito-cel successful concern with Gilead. Anito-cel is simply a BCMA-targeted CAR-T therapy akin to Legend Biotech and Johnson & Johnson’s Carvykti, showing comparable efficacy with a much benign neurological side-effect profile. Despite encouraging objective results for anito-cel, Arcellx detracted from show pursuing Johnson & Johnson’s announcement of beardown information for its Tecvayli (a BCMA bispecific) positive Darzalex operation successful antecedently treated, Darzalex-naïve patients, suggesting accrued contention for BCMA CAR-T therapies. Based connected our discussions with myeloma specialists, we deliberation BCMA CAR-T volition stay the preferred attraction enactment successful the 2nd enactment mounting for a important information of patients. We proceed to judge Arcellx’s cause is meaningfully differentiated connected information and expect shares to admit up of a imaginable 2026 launch."